BioCardia, Inc. reported financial results for the quarter ended June 30, 2026, announcing a net loss of $1.6 million compared to $2.0 million in the prior year period. The company raised approximately $4.9 million in net proceeds through its At-the-Market facility and held cash reserves of $4.1 million at quarter-end. Research and development expenses decreased to $0.9 million from $1.4 million, primarily due to the close-out of the CardiAMP HF Trial. BioCardia highlighted positive regulatory interactions, noting that Japan’s PMDA supports a Shonin pre-market submission for CardiAMP Cell Therapy in Q4 2026 and the FDA indicated ongoing trials may support U.S. approval. The company operates in the biotechnology industry, developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.

BioCardia, Inc. issued a press release on June 18, 2026, providing a business strategy update and highlighting business development opportunities. BioCardia, Inc. is a biotechnology company focused on developing and delivering cell therapy products.

BioCardia, Inc. announced that following a recent share sale via an "At The Market" offering agreement with H.C. Wainwright & Co., the company has regained compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement. Between April 1, 2026, and June 5, 2026, the company sold 4,004,330 shares at an average price of $1.27, generating $4.9 million in net proceeds. BioCardia, Inc. is a biotechnology company focused on developing cardiovascular therapies.

BioCardia, Inc. announced in a press release that it sold 3,509,604 shares of common stock at an average price of $1.279 per share on June 5, 2026, pursuant to its "At The Market" offering agreement with H.C. Wainwright & Co.